


Network of doctors who received direct and in-kind payments for GLP-1s is larger than every other drug

Number of doctors who have received at least one payment, 2018-2025



Includes payments for consulting, speaking, meals, travel and other expenses. Other diabetes drugs are SGLT2 inhibitors.